Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Buy” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company.

Several analysts have issued reports on BAYRY shares. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Finally, Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th.

Bayer Aktiengesellschaft Price Performance

BAYRY opened at $13.80 on Thursday. The company has a 50-day moving average of $11.83 and a 200-day moving average of $11.89. The company has a market capitalization of $54.23 billion, a P/E ratio of -21.56, a PEG ratio of 4.43 and a beta of 0.55. Bayer Aktiengesellschaft has a 1-year low of $7.19 and a 1-year high of $15.23. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The business had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.